Application of exogenous Cyclo(-RGDfK) polypeptide to preparation of medicines for preventing and treating hypertensive pulmonary arterial disease

A pulmonary arterial hypertension and pulmonary arterial technology, applied in the direction of drug combination, cyclic peptide components, cardiovascular system diseases, etc., to achieve the effect of reducing the weight ratio, reducing the systolic pressure of the right ventricle, and inhibiting the proliferation of pulmonary artery smooth muscle cells

Pending Publication Date: 2018-11-06
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, there is no report of exogenous Cyclo(-RGDfK) polypeptide in the preparation of drugs for the prevention and treatment of pulmonary hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of exogenous Cyclo(-RGDfK) polypeptide to preparation of medicines for preventing and treating hypertensive pulmonary arterial disease
  • Application of exogenous Cyclo(-RGDfK) polypeptide to preparation of medicines for preventing and treating hypertensive pulmonary arterial disease
  • Application of exogenous Cyclo(-RGDfK) polypeptide to preparation of medicines for preventing and treating hypertensive pulmonary arterial disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Application of exogenous Cyclo(-RGDfK) polypeptide in the preparation of drugs for preventing and treating pulmonary hypertension:

[0023] 1) Male SD rats (4 weeks old) were randomly divided into 3 groups: control group, pulmonary arterial hypertension group and exogenous RGD polypeptide treatment group. The specific operation of each treatment group is as follows ( figure 1 ):

[0024] Control group: intraperitoneal injection of normal saline with the same volume as monocrotaline injection.

[0025] Pulmonary hypertension group: a single intraperitoneal injection of monocrotaline (MCT, 40 mg / kg) to 4-week-old rats, followed by intraperitoneal injection of normal saline equivalent to the volume of monocrotaline every other day;

[0026] Treatment group: a single intraperitoneal injection of monocrotaline (MCT, 40 mg / kg) to 4-week-old rats, and simultaneous injection of exogenous Cyclo(-RGDfK) polypeptide ( Figure 5 ) (RGD, 5mg / kg), and inject exogenous Cyclo(-RGDfK...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of new applications of medicines and particularly discloses application of an exogenous Cyclo(-RGDfK) polypeptide to preparation of medicines for preventing and treating hypertensive pulmonary arterial disease. The applicant discovers that the exogenous Cyclo(-RGDfK) polypeptide is capable of controlling activity of Rac1 and RhoA in lung tissues of pulmonary hypertension model rats so as to inhibit proliferation of pulmonary artery smooth muscle cells of wild pulmonary hypertension model rats. The therapeutic study results show that the exogenous RGD polypeptide has therapeutic effects of obviously inhibiting proliferation of pulmonary artery smooth muscle cells, reducing the right ventricle systolic pressure and reducing the ratio of the weightof the right ventricle to the total weight of the left ventricle and the interventricular septum. The invention firstly discloses application of the exogenous Cyclo(-RGDfK) polypeptide to treatment of the hypertensive pulmonary arterial disease and provides the medicine basis for treating the hypertensive pulmonary arterial disease.

Description

technical field [0001] The invention belongs to the technical field of new application of medicines, and specifically relates to the application of exogenous Cyclo(-RGDfK) polypeptide in the preparation of medicines for preventing and treating pulmonary hypertension. Background technique [0002] Pulmonary hypertension (PH) is a clinical hemodynamic syndrome characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance. The important pathophysiological basis of its development is pulmonary vasoconstriction, proliferation of endothelial cells and smooth muscle cells, and in situ thrombus formation. This implies that there are perturbations in the normal relationships between vasodilators and vasoconstrictors, growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic determinants. These homeostatic imbalances may be a consequence of pulmonary vascular endothelial cell dysfunction or injury. PH can lead to right heart failure and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/12A61P9/12
CPCA61K38/12A61P9/12
Inventor 曾和松刘玉建王洪杰
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap